Sign In
Buy TAK
$17.09
-0.160 (-0.93%)
At Close: Jul 31, 2026
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
08:04am, Monday, 09'th Feb 2026
Privately held Iambic said on Monday it has entered a multi-year partnership worth more than $1.7 billion with Japan's Takeda Pharmaceutical to use artificial intelligence to help design small-molecul
Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules
08:00am, Monday, 09'th Feb 2026
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today ann
Takeda Tests New Highs, But Struggles To Find Entyvio Successor
02:10pm, Friday, 30'th Jan 2026
Takeda Pharmaceuticals is downgraded from buy to hold after reaching 52-week highs, with valuation no longer compelling. TAK's Q3 earnings were resilient despite US revenue declining 9.1%; margin impr
Takeda Pharmaceutical Company Limited (TAK) Q3 2026 Earnings Call Transcript
04:52pm, Thursday, 29'th Jan 2026
Takeda Pharmaceutical Company Limited (TAK) Q3 2026 Earnings Call Transcript
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incrementa
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL Ig
Dynasty Wealth Management LLC Takes Position in Takeda Pharmaceutical Co. $TAK
05:16am, Wednesday, 21'st Jan 2026
Dynasty Wealth Management LLC bought a new stake in shares of Takeda Pharmaceutical Co. (NYSE: TAK) during the third quarter, according to the company in its most recent filing with the Securities and
Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12:45am, Tuesday, 13'th Jan 2026
Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
07:00am, Monday, 05'th Jan 2026
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug App
Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
10:00am, Thursday, 18'th Dec 2025
Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial intelligence, succeeded in two late-stage studies.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Takeda Pharmaceutical (NYSE:TAK) vs. Siga Technologies (NASDAQ:SIGA) Head-To-Head Review
01:46am, Monday, 15'th Dec 2025
Siga Technologies (NASDAQ: SIGA - Get Free Report) and Takeda Pharmaceutical (NYSE: TAK - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two comp
Takeda Pharmaceutical Co. $TAK Shares Sold by Arrowstreet Capital Limited Partnership
03:24am, Monday, 08'th Dec 2025
Arrowstreet Capital Limited Partnership cut its holdings in shares of Takeda Pharmaceutical Co. (NYSE: TAK) by 13.0% in the undefined quarter, according to the company in its most recent disclosure wi
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results fro
Fisher Asset Management LLC Acquires 46,490 Shares of Takeda Pharmaceutical Co. $TAK
04:08am, Saturday, 06'th Dec 2025
Fisher Asset Management LLC raised its holdings in shares of Takeda Pharmaceutical Co. (NYSE: TAK) by 89.2% during the undefined quarter, according to its most recent filing with the Securities and Ex
